Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lymphoma

Known as: Lymphoma (Hodgkin's and Non-Hodgkin's), Reticulolymphosarcomas, Lymphomatous 
Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs… Expand
  • table 1
Review
2019
Review
2019
This guideline presents recommendations for the management of coeliac disease (CD) and other gluten-related disorders both in… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Review
2019
Review
2019
Glyphosate is the most widely used broad-spectrum systemic herbicide in the world. Recent evaluations of the carcinogenic… Expand
  • table 1
  • table 6
  • table 8
  • table 9
  • figure 2
Review
2019
Review
2019
Abstract The aim of this review was to review the basic background, technique, and clinical applications of arterial spin… Expand
Review
2019
Review
2019
Purpose Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T… Expand
  • table 1
  • figure 1
Review
2019
Review
2019
  • R. Roskoski
  • Pharmacological research
  • 2019
  • Corpus ID: 80625382
Because mutations, overexpression, and dysregulation of protein kinases play essential roles in the pathogenesis of many… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Review
2019
Review
2019
Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Review
2019
Review
2019
BACKGROUND Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the… Expand
Review
2019
Review
2019
PURPOSE Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Review
2018
Review
2018
In October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor (CAR) T… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2